Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The 2026 World Conference on Lung Cancer (WCLC) is shaping up to be a landmark event, with major data expected on novel antibody-drug conjugates (ADCs) targeting B7H3 in small cell lung cancer and long-awaited survival updates for EGFR-mutant non-small cell lung cancer. Stanford oncologist Dr. Heather Wakelee says several trials could be "practice-changing." Two presidential plenaries are on the agenda — a first for the conference — reflecting just how much new data is ready to be unveiled.
The 2026 IASLC World Conference on Lung Cancer (WCLC) is set to be one of the most data-rich editions yet, featuring two presidential plenaries — an unusual step that reflects the sheer volume of novel findings. Stanford oncologist and IASLC past president Dr. Heather Wakelee highlighted several trials she expects to reshape clinical practice across both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
In SCLC, all eyes are on two back-to-back phase 3 trials evaluating ADCs that target B7H3 — a protein increasingly recognized as a key target in small cell disease. The TAISHAN-302 trial tests YL201 plus topotecan vs. topotecan alone in relapsed SCLC, while ARTEMIS-008 compares HS-20093 to standard of care in patients who progressed on first-line platinum-based therapy. In NSCLC, the conference will unveil 8-year overall survival data from the landmark ADAURA trial (osimertinib in resected EGFR-mutant disease) and comparisons in EGFR exon 20 insertion tumors — including IV amivantamab (PAPILLON) and oral zipalertinib (REZILIENT3) in first-line settings.
Key Takeaways:
Why it matters: Lung cancer remains the leading cause of cancer death globally, and these trials represent the next wave of precision therapies. If the data hold up, clinicians could soon have new, more effective options for some of the hardest-to-treat lung cancer subtypes.
